It’s estimated that up to 60 percent of all people with lupus, and as many as two-thirds of all children with lupus, will develop kidney complications that require medical evaluation and treatment. Testing your urine is very important because there are so few symptoms of kidney disease.
There is a new study designed to evaluate the safety and efficacy of two different investigational drugs (filgotinib and GS-9876) in patients with lupus membranous nephropathy (LMN) who continue to have protein in their urine despite being treated with available therapies.
After an initial screening period, approximately 32 patients with LMN will be enrolled in this study.
Depending on how your body reacts to the study drug(s) at Weeks 1-16 and Weeks 16-32, your study doctor may switch you to the course of study drugs which had better results for you, regardless of the urine test results. The group and study drugs you are on will continue to be unknown to you and your study doctor.
Overall, this study will last up to about 1 year and 1 month, and during this time, you will visit the clinic at least 18 times. You may stop being in the study at any time.
The Lupus Foundation of America works to educate and inform about clinical trial study options available to people with lupus and the importance of getting involved to help advance lupus research. The Lupus Foundation of America does not endorse specific trials. More information about lupus and clinical trials in your area can be found by visiting the Lupus Foundation of America’s National Resource Center on Lupus.
 | 
